NANJING, Chine, le 2 sept. 2024 /PRNewswire/ — Le 2 septembre 2024, Simcere Zaiming, une société d’oncologie innovante du groupe Simcere Pharmaceutical (2096.HK), a annoncé un accord de collaboration avec Shenzhen TargetRx Inc. Ce partenariat porte sur l’inhibiteur de tyrosine kinase à…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.